Fox Run Management’s Quest Diagnostics DGX Stock Holding History

Fox Run Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,690	Closed	-$1.68M	–	962
2025 Q4	$1.68M	Buy	+9,690	New	+$1.76M	0.26%	50
2024 Q1	–	Sell	-6,884	Closed	-$949K	–	822
2023 Q4	$949K	Buy	6,884 +5,233	+317%	+$688K	0.24%	96
2023 Q3	$201K	Sell	1,651 -2,560	-61%	-$341K	0.06%	562
2023 Q2	$592K	Buy	+4,211	New	+$581K	0.17%	238
2019 Q3	–	Sell	-2,198	Closed	-$224K	–	405
2019 Q2	$224K	Sell	2,198 -572	-21%	-$55K	0.15%	332
2019 Q1	$249K	Buy	+2,770	New	+$240K	0.14%	328
2018 Q4	–	Sell	-5,933	Closed	-$640K	–	558
2018 Q3	$640K	Buy	+5,933	New	+$651K	0.28%	95
2018 Q1	–	Sell	-7,351	Closed	-$724K	–	758
2017 Q4	$724K	Buy	7,351 +3,851	+110%	+$365K	0.21%	150
2017 Q3	$328K	Sell	3,500 -2,900	-45%	-$308K	0.09%	450
2017 Q2	$711K	Buy	+6,400	New	+$677K	0.25%	115

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Fox Run Management's DGX Position: Q1 2026 in Review

Fox Run Management sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 9,690 shares — an estimated $1.68M sold.

Fox Run Management first reported a position in DGX in Q2 2017 and held it in 10 quarters. The position peaked at $1.68M in Q4 2025. 1,069 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Fox Run Management reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
Fox Run Management sold 9,690 Quest Diagnostics shares in Q1 2026, an estimated $1.68M.
Fox Run Management first reported a position in Quest Diagnostics in Q2 2017 and held it in 10 quarters.
Fox Run Management's Quest Diagnostics position peaked at $1.68M in Q4 2025.
1,069 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.